efficacyofr±beacopregimeninpatientswithpoor-prognosis.pdfVIP

中南大学学报（医学版） 2015, 40(8) htt p:// 858 J Cent South Univ (Med Sci) DOI:10.11817/j.issn.1672-7347.2015.08.006 /xbwk/fi leup/PDF/201508858.pdf R±BEACOP 方案对预后不良淋巴瘤的疗效研究 董菲，庞一帆，王晶，克晓燕 ( 北京大学第三医院血液科，北京 100191) [摘要] 目的：研究环磷酰胺、表阿霉素、长春新碱、强的松联合依托泊苷/替尼泊苷和/或博来霉素，有或无美 罗华(cyclophosphamideplus ，epirubicin ，vincristine ，prednisone plus etoposide and/or bleomycin ，with or without rituximab ， R ±BEACOP)方案对预后不良淋巴瘤的有效性。 方法：收集北京大学第三医院2002年至2012年间接受 1次以上R ± BEACOP方案治疗的89例预后不良淋巴瘤患者，采用回顾性分析的方法对其疗效进行分析。结果：治疗总反应率为 62.9%(56例) ，对于霍奇金淋巴瘤及T/NK细胞非霍奇金淋巴瘤的疗效较好。有效率在不同年龄、分期、国际预后指数 的患者中差异均无统计学意义(均P 0.05)。结论：R±BEACOP方案对部分预后不良患者依然有效，尤以霍奇金淋巴瘤 患者为著，可开展前瞻性大样本临床试验进一步评价其疗效。 [关键词] 淋巴瘤；R±BEACOP方案；总反应率 Efficacy of R±BEACOP regimen in patients with poor-prognosis lymphoma DONG Fei, PANG Yifan, WANG Jing, KE Xiaoyan (Department of Hematology, Peking University Th ird Hospital, Beijing 100191, China) ABSTRACT Objective: To analyze the efficacy of cyclophosphamideplus, epirubicin, vincristine, prednisone plus etoposide and/or bleomycin, with or without rituximab (R±BEACOP) regimen in patient with poor-prognosis lymphoma. Methods: A total of 89 patients, who had poor-prognosis lymphoma and received at least 1 cycle of R±BEACOP regimen during 2002 to 2012, were enrolled and analyzed by a retrospective study. Results: The rate of complete response was 62.9% (56 patients). The efficacy of Hodgkin lymphoma (HL) and T/NK NHL was better than that of other types of lymphoma. There